SPRY ALERT: Securities Fraud Class Action Launched Against ARS Pharmaceuticals, Inc. - October 5, 2026 Deadline
Levi & Korsinsky LLP announced a securities fraud class action against ARS Pharmaceuticals on behalf of investors who purchased SPRY securities between March 9, 2026 and June 24, 2026, with an October 5, 2026 lead plaintiff deadline. The complaint alleges defendants made misleading statements about the expected timeline for expanded insurance coverage of neffy through CVS Caremark, which deferred its decision to January 2027 after the company missed its guided July 1, 2026 coverage deadline. The release highlights that SPRY stock fell from $10.54 to $8.02 across June 24-25, 2026, a 23.9% single-day decline following the coverage-miss disclosure.
Key figures
- Class period
- March 9, 2026 to June 24, 2026
- One day decline pct
- -23.9%
- Price after decline
- 8.02
- Price before decline
- 10.54
- Lead plaintiff deadline
- October 5, 2026
- Cvs caremark decision deferred to
- January 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.